- The Washington Times - Sunday, December 25, 2005


In an unusually candid admission, the federal chief of AIDS research says he thinks drug companies don’t have an incentive to create a vaccine for HIV and are likely to wait to profit from it after the government develops one.

The government thus has had to spend more time focusing on the processes that drug companies ordinarily follow in developing medicines and bringing them to market, said Dr. Edmund Tramont, head of the AIDS research division of the National Institutes of Health.

“We had to spend some time and energy paying attention to those aspects of development because the private side isn’t picking it up,” Dr. Tramont testified in July in a deposition in a whistleblower employment lawsuit obtained by the Associated Press.

Dr. Tramont predicted that the government eventually will create a vaccine.

“If we look at the vaccine, HIV vaccine, we’re going to have an HIV vaccine. It’s not going to be made by a company,” he said. “They’re dropping out like flies because there’s no real incentive for them to do it. We have to do it.”

“They will eventually — if it works, they won’t have to make that big investment. And they can make it and sell it and make a profit,” he said.

An official of the group representing the country’s major drug companies took exception to Dr. Tramont’s comments.

“That is simply not true. America’s pharmaceutical research companies are firmly committed to HIV/AIDS vaccine research and development, with 15 potential vaccines in development today,” said Ken Johnson, senior vice president of communications at the Pharmaceutical Research and Manufacturers of America.

“Vaccine research is crucial to controlling the AIDS pandemic, and our companies are well aware of the need to succeed in this vital area of science,” Mr. Johnson said.

In an e-mail response for comment, Dr. Tramont said the HIV vaccine mirrors the history of other vaccines.

“It is not just a HIV vaccine — it’s all vaccines — that is why there was/is a shortage of flu vaccines,” Dr. Tramont wrote.

The quest for an AIDS vaccine has been one of science’s biggest disappointments despite billions of dollars in investment and years of research. Part of the problem is that such a vaccine must work through the very immune system that AIDS compromises.

The failure in the past several years of one of the more promising vaccine candidates has bred some frustration.

The United Nations’ top HIV/AIDS official acknowledged earlier this year at a conference that it no longer was realistic to hope that the world will meet its goal of halting and reversing the spread of the disease by 2015. A British delegate to the conference predicted it might take 20 years before such a vaccine is created.

The International AIDS Vaccines Initiative (IAVI), a nonprofit group that is pushing for an AIDS vaccine, said more than 30 vaccine candidates are being tested mostly on a small scale in 19 countries, but it acknowledges that many are pursuing a similar theory of science that could prove futile.

“If the hypothesis is proven incorrect, the pipeline of candidates now in trials will be rendered mostly irrelevant. Strong alternative hypotheses have been largely neglected,” the group said.

IAVI estimates that total annual spending on an AIDS vaccine is $682 million.

“This represents less than 1 percent of total spending on all health product development,” IAVI said. “Private-sector efforts amount to just $100 million annually. This is mainly due to the lack of incentives for the private sector to invest in an AIDS vaccine — the science is difficult, and the developing countries that need a vaccine most are least able to pay.”

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide